GB Patent

GB2388594A — Imidazo-triazine PDE 4 inhibitors

Assigned to Bayer AG · Expires 2003-11-19 · 22y expired

What this patent protects

The invention relates to novel 2-(substituted phenyl or pyridyl)-5-ethyl-7-cycloalkyl-imidazotriazinones, processes for their preparation and their use in medicaments as PDE 4 inhibitors esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

USPTO Abstract

The invention relates to novel 2-(substituted phenyl or pyridyl)-5-ethyl-7-cycloalkyl-imidazotriazinones, processes for their preparation and their use in medicaments as PDE 4 inhibitors esp. for the treatment and/or prophylaxis of inflammatory processes and/or immune diseases.

Drugs covered by this patent

Patent Metadata

Patent number
GB2388594A
Jurisdiction
GB
Classification
—
Expires
2003-11-19
Drug substance claim
No
Drug product claim
No
Assignee
Bayer AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.